Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Kanada - Inggris - Health Canada

fresenius kabi canada ltd - fish oil; dextrose; lysine (lysine acetate); phenylalanine; leucine; valine; threonine; methionine; isoleucine; tryptophan; alanine; arginine; glycine; proline; histidine; serine; taurine; tyrosine; sodium acetate trihydrate; potassium chloride; sodium glycerophosphate; magnesium sulfate; calcium chloride; zinc sulfate heptahydrate; soybean oil; medium chain triglycerides (mct); olive oil - emulsion - 0.57g; 12.7g; 0.34g; 0.26g; 0.38g; 0.31g; 0.22g; 0.22g; 0.25g; 0.1g; 0.71g; 0.61g; 0.56g; 0.57g; 0.15g; 0.33g; 0.05g; 0.02g; 0.17g; 0.23g; 0.21g; 0.061g; 0.028g; 0.00066g; 1.14g; 1.14g; 0.95g - fish oil 0.57g; dextrose 12.7g; lysine (lysine acetate) 0.34g; phenylalanine 0.26g; leucine 0.38g; valine 0.31g; threonine 0.22g; methionine 0.22g; isoleucine 0.25g; tryptophan 0.1g; alanine 0.71g; arginine 0.61g; glycine 0.56g; proline 0.57g; histidine 0.15g; serine 0.33g; taurine 0.05g; tyrosine 0.02g; sodium acetate trihydrate 0.17g; potassium chloride 0.23g; sodium glycerophosphate 0.21g; magnesium sulfate 0.061g; calcium chloride 0.028g; zinc sulfate heptahydrate 0.00066g; soybean oil 1.14g; medium chain triglycerides (mct) 1.14g; olive oil 0.95g - replacement preparations

Amerika Serikat - Inggris - NLM (National Library of Medicine)

fresenius kabi usa, llc - zinc chloride (unii: 86q357l16b) (zinc cation - unii:13s1s8sf37) - zinc cation 250 ug in 1 ml

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - caspofungin - pdr/conc/soln for infus - 50 milligram - other mycotics for systemic use

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - caspofungin - pdr/conc/soln for infus - 70 milligram - other mycotics for systemic use

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 400 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).